Saudi Arabia offers Red Sea oil transport option to crude buyers in response to the Strait of Hormuz crisis

金十2026/03/16 05:41

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Golden Ten Data reported on March 16 that, given the possibility of prolonged disruption in the Strait of Hormuz, Saudi Arabia is offering its long-term crude oil customers the option to receive April oil supplies via the Yanbu port on the Red Sea. According to traders who have received notification from Saudi Aramco, due to limited pipeline transport capacity to the port, buyers choosing Yanbu can only receive a portion of their contracted supply each month. Another option is to receive oil from the Persian Gulf, but if the strait remains closed, there is a risk of not receiving any oil at all. Traders stated that if the war continues, oil loaded at Yanbu and shipped to Asia is likely to be sold on a delivered basis, meaning Saudi Aramco would be responsible for transportation logistics, rather than the usual shipment method where customers arrange their own shipping. They noted that currently, the oil supplied to refiners via Yanbu is limited to the Arab Light crude variety.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)

路透社•2026/10/08 16:11